JNJ

On the surface JNJ looks like a quality machine firing on all cylinders: FY2025 revenue of $94.2B (+6.0%), gross margin of 67.9%, operating margin of 22.9%, ROE of 32.9%, and $24.5B of operating cash flow against ~$4.8B of capex (≈$19.7B free cash flow). The franchise is genuinely durable — two scaled segments (Innovative Medicine and MedTech) spanning 63 manufacturing plants, $169B of retained earnings, and a manageable 1.44x liabilities/equity. This is a blue-chip compounder, and nothing in the filing challenges that core quality.

The catch is earnings quality. Reported net income jumped +90.6% to $26.8B and diluted EPS +90.5% to $11.03, but that is not an operational result. The income statement shows 'Other (income) expense, net' swinging from a $4,694M expense in 2024 to $7,209M of income in 2025 — an ~$11.9B favorable swing that accounts for nearly the entire move in pre-tax earnings ($16,687M → $32,581M). Strip it out and the real engine is mid-single-digit: revenue +6%, gross margin actually compressed (~69%→67.9%) as cost of products sold grew +10% vs +6% sales, and R&D fell ~15% ($17,232M → $14,665M; the XBRL '$109M' tag is an artifact). Reported $11.03 overstates true earning power — normalized EPS is closer to ~$8.50–9, putting the multiple in the mid-20s rather than the headline 20.7x.